Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fenoldopam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 known ✓ | P21728 | 17/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | RECQL | P46063 | 4/20 | 1.00 |
| ▸ | BLM | P54132 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 8/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.97 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.97 |
| ▸ | THPO | P40225 | 2/20 | 0.97 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.97 |
| ▸ | DRD3 | P35462 | 2/20 | 0.97 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.97 |
| ▸ | TSHR | P16473 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fenoldopam SCHEMBL11215595 | 1.00 | KDM4E (1.00) | KDM4ERECQLBLMPOLBPMP22 | |
| Fenoldopam SCHEMBL1815791 | 0.99 | DRD1 (1.00) | KDM4ERECQLBLMPOLBPMP22 | |
| Fenoldopam SCHEMBL13287212 | 0.99 | DRD1 (1.00) | KDM4ERECQLBLMPOLBPMP22 | |
| Fenoldopam SCHEMBL34250 | 0.99 | DRD1 (1.00) | KDM4ERECQLBLMPOLBPMP22 | |
| Fenoldopam SCHEMBL9157427 | 0.99 | DRD1 (1.00) | KDM4ERECQLBLMPOLBPMP22 | |
| Fenoldopam SCHEMBL41214 | 0.99 | DRD1 (1.00) | KDM4ERECQLBLMPOLBPMP22 | |
| Fenoldopam SCHEMBL9157381 | 0.97 | DRD1 (0.97) | KDM4ERECQLBLMPOLBPMP22 | |
| Fenoldopam SCHEMBL29424282 | 0.97 | DRD1 (0.97) | KDM4ERECQLBLMPOLBPMP22 | |
| Fenoldopam SCHEMBL16241872 | 0.97 | DRD1 (0.97) | KDM4ERECQLBLMPOLBPMP22 | |
| Fenoldopam SCHEMBL3136078 | 0.93 | GFER (0.91) | KDM4ERECQLBLMPOLBPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1917277-A4 | KILLING HUMAN LYMPHOMA AND LEUKEMIA CANCER CELLS AND TCR-ACTIVATED NORMAL HUMAN CELLS BY DOPAMINE D1R AGONISTS | LEVITE MIA (IL) | 2009-08-05 | — | — | EP | claimed |
| US-20080311657-A1 | Killing Human Lymphoma and Leukemia Cancer Cells and Tcr-Activated Normal Human Cells By Dopamine D1r Agonists | LEVITE MIA | 2008-12-18 | — | — | US | claimed |
| EP-1917277-A2 | KILLING HUMAN LYMPHOMA AND LEUKEMIA CANCER CELLS AND TCR-ACTIVATED NORMAL HUMAN CELLS BY DOPAMINE D1R AGONISTS | Mineuet Therapeutics Ltd. (IL) | 2008-05-07 | — | — | EP | claimed |
| WO-2007019266-A2 | KILLING HUMAN LYMPHOMA AND LEUKEMIA CANCER CELLS AND TCR-ACTIVATED NORMAL HUMAN CELLS BY DOPAMINE D1R AGONISTS | MINEUET THERAPEUTICS LTD. (IL) | 2007-02-15 | — | — | WO | claimed |
| US-20240065999-A1 | Ophthalmic Formulation Containing a Dopaminergic Prodrug that may be Combined with One or More Agents | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2024-02-29 | — | — | US | disclosed |
| WO-2022099195-A1 | OPHTHALMIC FORMULATION CONTAINING A DOPAMINERGIC PRODRUG THAT MAY BE COMBINED WITH ONE OR MORE AGENTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-05-12 | — | — | WO | disclosed |
| US-11246873-B2 | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-02-15 | — | — | US | disclosed |
| US-11052154-B2 | Ras protein degradation inducing molecule and pharmaceutical composition | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2021-07-06 | — | — | US | disclosed |
| US-11007269-B2 | P53 degradation inducing molecule and pharmaceutical composition | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2021-05-18 | — | — | US | disclosed |
| US-20210088504-A1 | PROTEIN DEGRADATION INDUCING TAG AND USAGE THEREOF | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2021-03-25 | — | — | US | disclosed |
| US-20200390780-A1 | DIRECTED DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2020-12-17 | — | — | US | disclosed |
| US-10660899-B2 | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-05-26 | — | — | US | disclosed |
| EP-0087319-A1 | R- and S-isomers of 6-chloro-7,8-dihydroxy-1-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine | SMITHKLINE BECKMAN CORPORATION (US) | 1983-08-31 | — | — | EP | disclosed |
| EP-0004794-B1 | SUBSTITUTED BENZAZEPINES, PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITHKLINE BECKMAN CORPORATION (US) | 1982-04-28 | — | — | EP | disclosed |
| US-4321195-A | 6-Halo-7,8-dimethoxy-1-(methoxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepines | SMITHKLINE CORPORATION (US) | 1982-03-23 | — | — | US | disclosed |
| EP-0022330-A2 | Synergistic antihypertensive compositions | SMITHKLINE BECKMAN CORPORATION (US) | 1981-01-14 | — | — | EP | disclosed |
| US-4197297-A | 6-Halo-7,8-dihydroxy-1-(hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepines | SMITHKLINE CORPORATION (US) | 1980-04-08 | — | — | US | disclosed |
| EP-0004794-A2 | Substituted benzazepines, processes for preparing them and pharmaceutical compositions containing them | SMITHKLINE BECKMAN CORPORATION (US) | 1979-10-17 | — | — | EP | disclosed |
| US-4171359-A | DOPAMINERGIC ACTIVITY | SMITHKLINE CORPORATION (US) | 1979-10-16 | — | — | US | disclosed |
| US-4160765-A | Method for 6-bromination of 1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine compounds | SMITHKLINE CORPORATION (US) | 1979-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240065999-A1 | Ophthalmic Formulation Containing a Dopaminergic Prodrug that may be Combined with One or More Agents | SLC6A3, SLC18A2, SLC6A2 | DRD1 29/4885KDM4E 3477/4885RECQL 3266/4885 |
| US-11052154-B2 | Ras protein degradation inducing molecule and pharmaceutical composition | KRAS, G3BP1, NRAS | DRD1 4143/4885KDM4E 4086/4885RECQL 3481/4885 |
| US-20210088504-A1 | PROTEIN DEGRADATION INDUCING TAG AND USAGE THEREOF | SENP8, SENP6, SENP7 | DRD1 4114/4885KDM4E 2997/4885RECQL 4253/4885 |
| US-11007269-B2 | P53 degradation inducing molecule and pharmaceutical composition | TP53, TP53BP1, MDM2 | DRD1 4025/4885KDM4E 4133/4885RECQL 1548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.